Comparative effectiveness of sleeve gastrectomy and semaglutide for weight loss and metabolic outcomes: a prospective non-randomized study

Jan 22, 2026BMC medicine

Weight loss and metabolic changes after sleeve gastrectomy compared to semaglutide treatment

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

At 12 months, mean percentage total weight loss was 28.6% for compared to 11.3% for once-weekly .

Sleeve gastrectomy resulted in significantly greater weight loss at all measured time points compared to semaglutide.
Mean body mass index decreased more substantially in the sleeve gastrectomy group than in the semaglutide group.
Both interventions led to metabolic improvements, but sleeve gastrectomy was associated with larger reductions in triglycerides and increases in HDL cholesterol.
Among patients who stopped semaglutide after 6 months, a majority experienced weight regain within 12 months.

AI simplified

BACKGROUND: Bariatric surgery and pharmacotherapy represent two major strategies for the treatment of obesity. (SG) is the most widely performed surgical procedure and is supported by long-term evidence, while , a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has recently emerged as an effective medical therapy. However, prospective real-world studies directly comparing these interventions are limited.

METHODS: We conducted a prospective, non-randomized trial at a single tertiary center (ChiCTR2300070632). Adults with obesity were allocated to SG (n = 36) or once-weekly semaglutide (n = 35) based on shared decision-making. Semaglutide was administered for a planned duration of 24 weeks, after which continuation or discontinuation was determined by patient preference. Primary outcomes were percentage total weight loss (%TWL) and changes in body mass index (BMI) at 1, 3, 6, and 12 months. Secondary outcomes included changes in metabolic parameters.

RESULTS: SG achieved significantly greater weight loss at all time points. At 12 months, mean %TWL was 28.6% for SG versus 11.3% for semaglutide (p < 0.001). Mean BMI decreased from 32.7 ± 2.8 to 23.8 ± 2.6 kg/min the SG group and from 32.0 ± 2.6 to 28.4 ± 4.0 kg/min the semaglutide group (p < 0.001). Both groups demonstrated metabolic improvements, but SG was associated with greater reductions in triglycerides and greater increases in high-density lipoprotein cholesterol (HDL-C). Among patients who discontinued semaglutide after 6 months (n = 25), mean weight increased from 74.6 ± 11.3 to 83.2 ± 12.3 kg by 12 months, with 32% regaining to baseline weight or higher. 2 2

CONCLUSIONS: SG achieved greater weight loss and improvements in triglycerides and HDL-C compared with semaglutide. Semaglutide was effective during treatment, but many patients experienced weight regain after discontinuation.

TRIAL REGISTRATION: Trial Registry No. ChiCTR2300070632 (2023 April 19).

Key numbers

28.6%

Weight Loss % Increase

Mean %TWL at 12 months for vs.

32%

Weight Regain %

Percentage of patients regaining weight to baseline or higher after stopping

0.94 mmol/L

Triglycerides Reduction Increase

Change in triglycerides after 6 months for vs.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (HTML) ↗View full text (PDF) ↗

Featured in

GLP-1 TherapiesIssue #21

GLP-1 drugs may fight addiction, and reduce alcohol consumption

↗

Comparative effectiveness of sleeve gastrectomy and semaglutide for weight loss and metabolic outcomes: a prospective non-randomized study

Abstract

Key numbers

Full Text

Featured in

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Related papers

Featured in

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief